After patients with Cancer undergo surgery to remove a tumour. Sometimes they also undergo chemotherapy, tools are used to identify patients at the highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value.
In a new study published in Clinical Cancer Research, a team led by investigators at Massachusetts General Hospital has evaluated the first tumor-uninformed test that detects cancer DNA circulating in the Blood of patients following treatment. The test is called Guardant Reveal which was developed by precision oncology company Guardant Health. It is tumor-uninformed because this test does not require knowing the particular mutations that were present in the patient’s tumor.
In this study, Parikh and her colleagues at Massachusetts General Hospital and Guardant Health evaluated the first tumor-uninformed ctDNA assay to detect residual Cancer cells in patients who underwent surgery for colorectal cancer. They decided that instead of relying on DNA sequencing of individual patient’s tumors, the approach looked for known cancer-specific alterations.